Title :

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.

Author(s) :

de Moura, Alexandre [Auteur]
Institut Curie [Paris]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Vuagnat, P. [Auteur]
Institut Curie [Paris]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Renouf, B. [Auteur]
Pierga, J. Y. [Auteur]
Loirat, D. [Auteur]
Institut Curie [Paris]
Vaflard, Pauline [Auteur]
Institut Curie [Paris]
Lafayolle De La Bruyère, C. [Auteur]
Chaumard-Billotey, N. [Auteur]
Hajjaji, Nawale [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Ladoire, Sylvain [Auteur]
Département d'oncologie médicale [Centre Georges-François Leclerc]
Dabakuyo-Yonli, Tienhan Sandrine [Auteur]
Département d'oncologie médicale [Centre Georges-François Leclerc]
Patsouris, A. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Frenel, J. S. [Auteur]
Nicolai, V. [Auteur]
Institut Claudius Regaud [ICR]
Alexandre, M. [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Dohollou, N. [Auteur]
Polyclinique Bordeaux Nord Aquitaine [PBNA]
Grenier, J. [Auteur]
Institut Sainte Catherine [Avignon]
Bourien, H. [Auteur]
Département d'oncologie médicale [Rennes]
Bidard, F. C. [Auteur]
Institut Curie [Paris]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]

Journal title :

Scientific Reports

Abbreviated title :

Sci Rep

Volume number :

13

Pages :

13427

Publication date :

2023-08-28

ISSN :

2045-2322

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel ...
Show more >Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab as first line therapy. This EAP was later discontinued when the IMpassion131 trial read out with negative results. We performed a retrospective multicentric analysis in patients who were prospectively enrolled in the French EAP. Efficacy and toxicity data were obtained on 64 patients treated from August 2019 to August 2020 in 10 French cancer centers. Median progression-free survival (PFS) and overall survival (OS) were 4.1 months (95% CI [3.0–5.8]) and 17.9 months (95% CI [12.4–NR]), respectively. The 6-months PFS rate was 28% (95% CI [16–40%]) (N = 18/64), while N = 33/64 patients (52%, 95% CI [38–63%]) experienced a tumor response. Exploratory subgroup analyses retrieved that corticosteroid use at inclusion in the EAP, before treatment initiation, was the only independent unfavorable prognostic factor for PFS (HR 2.7, 95% CI [1.3–5.6]). No new safety signal was observed. This real-life study, unique by its setting (EAP granted by anticipation and later withdrawn), suggests atezolizumab and paclitaxel has a limited efficacy in PD-L1-positive aTNBC, especially in patients receiving corticosteroids as comedication before treatment start.Show less >

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2023-12-13T03:39:14Z
2024-01-23T15:10:41Z